Tatiane Yanes

Tatiane Yanes

Auto-generated profile, based on publicly available information

Tatiane Yanes

Frazer Institute, The University of Queensland, Dermatology Research Centre, Brisbane, Australia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2020 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
TYTatiane Yanes
Tatiane Yanes
MYMary-Anne Young
Mary-Anne Young
BMBettina Meiser
Bettina Meiser
PJPaul James
Paul James
Polygenic factors are estimated to account for an additional 18% of the familial relative risk of breast cancer, with those at the highest level of polygenic risk distribution having a least a twofold increased risk of the disease. Polygenic testing promises to revolutionize health services by providing personalized risk assessments to women at high-risk of breast cancer and within population breast screening programs. However, implementation of polygenic testing needs to be considered in light of its current limitations, such as limited risk prediction for women of non-European ancestry. This article aims to provide a comprehensive review of the evidence for polygenic breast cancer risk, including the discovery of variants associated with breast cancer at the genome-wide level of significance and the use of polygenic risk scores to estimate breast cancer risk. We also review the different applications of this technology including testing of women from high-risk breast cancer families with uninformative genetic testing results, as a moderator of monogenic risk, and for population screening programs. Finally, a potential framework for introducing testing for polygenic risk in familial cancer clinics and the potential challenges with implementing this technology in clinical practice are discussed.

11 September 2018 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
TYTatiane Yanes
Tatiane Yanes
AWAmanda M. Willis
Amanda M. Willis
BMBettina Meiser
Bettina Meiser
KTKatherine M. Tucker
Katherine M. Tucker
MBMegan Best
Megan Best
Psychosocial and behavioral outcomes of genetic testing in oncology are well known, however, it is unclear how these findings will generalize to more complex genomic testing. The aim of this systematic review was to assess the psychosocial and behavioral outcomes of cancer genomic testing. Studies were selected for inclusion if they were published from January 2003 to January 2017 and addressed psychological and behavioral outcomes of cancer genomic testing in adults. A review of four databases identified 9620 abstracts, with 22 publications meeting the inclusion criteria. Of the included articles, 11 studies reported on outcomes of germline testing, with three articles assessing panel testing and eight SNP testing. No studies assessed the outcomes of WGS or WES. Eleven articles assessed the outcomes of somatic testing, including testing for cancer prognosis and for personalized therapies. Studies were biased toward breast cancer and Caucasian women with high education and socioeconomic status. While studies demonstrated limited adverse psychological outcomes associated with genomic testing, a lack of consistency in psychosocial measures precluded any meta-analysis. Changes in health behavior following positive results were limited, and in some cases risk perception was not altered following genomic testing. There is limited evidence of adverse psychosocial outcomes and changes in health behavior following genomic testing to assess cancer risk. Findings from this review highlight the need for longitudinal research with superior methodological and theoretical design.

27 November 2013 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
LJLeila Jamal
Leila Jamal
JSJulie C Sapp
Julie C Sapp
KLKatie Lewis
Katie Lewis
TYTatiane Yanes
Tatiane Yanes
FFFlavia M Facio
Flavia M Facio
BBBarbara B Biesecker
Barbara B Biesecker
Respecting the confidentiality of personal data contributed to genomic studies is an important issue for researchers using genomic sequencing in humans. Although most studies adhere to rules of confidentiality, there are different conceptions of confidentiality and why it is important. The resulting ambiguity obscures what is at stake when making tradeoffs between data protection and other goals in research, such as transparency, reciprocity, and public benefit. Few studies have examined why participants in genomic research care about how their information is used. To explore this topic, we conducted semi-structured phone interviews with 30 participants in two National Institutes of Health research protocols using genomic sequencing. Our results show that research participants value confidentiality as a form of control over information about themselves. To the individuals we interviewed, control was valued as a safeguard against discrimination in a climate of uncertainty about future uses of individual genome data. Attitudes towards data sharing were related to the goals of research and details of participants’ personal lives. Expectations of confidentiality, trust in researchers, and a desire to advance science were common reasons for willingness to share identifiable data with investigators. Nearly, all participants were comfortable sharing personal data that had been de-identified. These findings suggest that views about confidentiality and data sharing are highly nuanced and are related to the perceived benefits of joining a research study.

3 July 2021 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
ASAmelia K. Smit
Amelia K. Smit
ASAshleigh R. Sharman
Ashleigh R. Sharman
DEDavid Espinoza
David Espinoza
CWCourtney Wallingford
Courtney Wallingford
MYMary‐Anne Young
Mary‐Anne Young
TYTatiane Yanes
Tatiane Yanes

2 November 2022 in Genetics in Medicine
Verified
Journal Article
Closed access
CWCourtney K. Wallingford
Courtney K. Wallingford
HKHannah Kovilpillai
Hannah Kovilpillai
CJChris Jacobs
Chris Jacobs
ETErin Turbitt
Erin Turbitt
CPClare A. Primiero
Clare A. Primiero
TYTatiane Yanes
Tatiane Yanes

17 December 2018 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
SSSian Karen Smith
Sian Karen Smith
ACAntonia Cai
Antonia Cai
MWMichelle Wong
Michelle Wong
MSMariana S Sousa
Mariana S Sousa
MPMichelle Peate
Michelle Peate
MBMargot Barclay
Margot Barclay
Access to information about prenatal screening is important particularly in light of new techniques such as non-invasive prenatal testing (NIPT). This study aimed to develop and examine the acceptability of a low literacy decision aid (DA) about Down syndrome screening among pregnant women with varying education levels and GPs. We developed a DA booklet providing information about first-trimester combined testing, maternal serum screening, and NIPT. GPs and women participated in a telephone interview to examine the acceptability of the DA and measure screening knowledge before and after reading the DA. The knowledge measure was designed to assess whether women had understood the gist of the information presented in the decision aid. It comprised conceptual questions (e.g. screening tells you the chance of having a baby with Down syndrome) and numeric questions (e.g. the accuracy of different screening tests). Twenty-nine women and 18 GPs participated. Regardless of education level, most women found the booklet ‘very’ clearly presented (n = 22, 76%), and ‘very’ informative (n = 23, 80%). Overall, women’s conceptual and numeric knowledge improved after exposure to the DA, from 4% having adequate knowledge to 69%. Women’s knowledge of NIPT also improved after receiving the decision aid, irrespective of education. Most GPs found it ‘very’ clearly presented (n = 13, 72%), and that it would ‘very much’ facilitate decision-making (n = 16, 89%). The DA was found to be acceptable to women as well as GPs. A comprehensive evaluation of the efficacy of the decision aid compared to standard information is an important next step. Strategies are needed on how to implement the tool in practice.